AMENDMENTS TO THE CLAIMS:

This listing of claims replaces the listing of claims in the application.

Listing of Claims:

~~**CLAIMS**~~

~~**COMBINATIONS OF GROWTH REGULATING FACTORS AND HORMONES FOR THE TREATMENT OF NEOPLASIA**~~

What is claimed is:

1- (Currently Amended) A ~~Pharmaceutical~~ pharmaceutical ~~combinations~~ combination for the treatment of neoplasia through simultaneous, separate, or sequential administration, comprising a compound A and B, wherein A is ~~and B are~~ selected from the group of molecules consisting ~~in~~ of:

~~A:~~

~~a.~~1. GnRH, or its analogues, or anti-GnRH antibodies, or GnRH receptor (GnRH-R), or its mutated variants, or derivative peptides, or anti-GnRH-R antibodies, coupled or not to an immunopotentiating carrier protein~~.~~;

~~a.~~2. ~~Natural~~ natural or recombinant gonadotropins, or their analogues, or their mutated variants, coupled or not to an immunopotentiating carrier protein, hypophyseal anti-gonadotropin antibody, their Fags, scFV fragments, humanized or not~~.~~;

~~a.~~3. ~~Hypophyseal Gonadotropin~~ hypophyseal gonadotropin receptors, or their mutated variants, or derivative peptides, coupled or not to an immunopotentiating carrier protein~~.~~; and

~~a.~~4. ~~Hypophyseal Gonadotropin~~ hypophyseal gonadotropin anti-receptor antibodies, their Fabs, scFV fragments, humanized or not~~.~~;

~~B:~~

and wherein B is selected from the group of molecules consisting of:

~~b.~~1. ~~Natural~~ natural or recombinant EGF or its mutated variants, or derivative peptides, or EGF mimetic peptides, or EGF analogues, coupled or not to an immunopotentiating carrier protein~~.~~;

~~b.~~2. ~~Anti-EGF~~ anti-EGF antibodies, their FabsscFV fragments, humanized or not~~.~~;

~~b.~~3. EGF receptor (EGF-R), or its mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein~~.~~;

~~b.~~4. ~~Anti-EGF~~ anti-EGF receptor antibodies, their Fabs, scFV fragments, humanized or not~~.~~;

~~b.~~5. ~~Natural~~ natural or recombinant VEGF or mutated variants, or derivative peptides, or VEGF mimetic peptides, or VEGF analogues, coupled or not to an immunopotentiating carrier protein~~.~~;

~~b.~~6. ~~Anti-VEGF~~ anti-VEGF antibodies, their Fabs, scFV fragments, humanized or not~~.~~;

~~b.~~7. VEGF receptors, or mutated variants, or derivative peptides from VEGF receptors, coupled or not to an immunopotentiating carrier protein~~.~~;

~~b.~~8. ~~Anti-VEGF~~ anti-VEGF receptor antibodies, their Fabs, scFV fragments, humanized or not~~.~~;

~~b.~~9. ~~Natural~~ natural or recombinant TGFor mutated variants, or derivative peptides, or TGF mimetic peptides, or TGF analogues, coupled or not to an immunopotentiating carrier protein~~.~~;

~~b.~~10. ~~Anti-TGF~~ anti-TGF antibodies, their Fabs, scFV fragments, humanized or not~~.~~; and

~~b.~~11 TGF receptor (TGF-R), or mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein.

2- (Currently Amended) ~~Combinations~~ A combination according to claim 1, wherein the A and B group of molecules are coupled to the immunopotentiating carrier protein by conjugation or the formation of chimeric proteins.

3- (Currently Amended) ~~Combinations~~ A combination according to ~~claims~~ claim 1 ~~and~~ ~~2~~, wherein the GnRH analogue peptide has sequence pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly, coupled to an immunopotentiating carrier protein.

4- (Currently Amended) ~~Combinations~~ A combination according to ~~claims~~ claim 1 ~~and~~ ~~2~~, wherein the immunopotentiating carrier protein is selected from *Neisseria meningitides* P1 and P64 outer membrane proteins.

5- (Currently Amended) ~~Combinations~~ A combination according to ~~claims~~ claim 1 ~~and~~ ~~2~~, wherein the immunopotentiating carrier protein is a Tetanic Toxoid (TT) T helper epitope.

6- (Currently Amended) ~~Combinations~~ A combination according to ~~claims~~ claim 1 ~~and~~ ~~2~~, wherein the conjugated chimeric protein is one of the following variants:

a) GnRH bound to a carrier protein and to EGF~~.~~;
b) GnRH bound to a carrier protein and to VEGF~~.~~;
c) GnRH bound to a carrier protein and to TGF~~.~~;
d) GnRH bound to a carrier protein, to EGF and TGF~~.~~; or
e) GnRH bound to a carrier protein, to VEGF and EGF.

7- (Currently Amended) A method for the generation of combined immune response comprising treatment with ~~one of~~ the therapeutic ~~combinations~~ combination ~~defined in any claims from~~ according to claim 1 ~~to 6~~.

8- (Currently Amended) A method according to claim 7, wherein the ~~combinations~~ combination can be applied simultaneously, separately, or sequentially.